Helicobacter pylori resistance to metronidazole and clarithromycin in Ireland

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 9, 2010, Pages 1123-1127

  O'Connor, Anthony ^a   Taneike, Ikue ^a   Nami, Abdurrazag ^a   Fitzgerald, Niamh ^a   Murphy, Philip ^a   Ryan, Barbara ^a   O'Connor, Humphrey ^a   Qasim, Asghar ^a   Breslin, Niall ^a   O'Moráin, Colm ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

clarithromycin; Helicobacter pylori; metronidazole; resistance

Indexed keywords

AGAR; AMOXICILLIN; CLARITHROMYCIN; MACROLIDE; METRONIDAZOLE; NITROIMIDAZOLE; PROTON PUMP INHIBITOR;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM ISOLATE; CHLAMYDIASIS; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; IRELAND; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL;

ADULT; ANTI-BACTERIAL AGENTS; BIOPSY; CLARITHROMYCIN; DRUG RESISTANCE, BACTERIAL; FEMALE; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; IRELAND; MALE; METRONIDAZOLE; MIDDLE AGED; PREVALENCE;

EID: 77955473589     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328338e43d     Document Type: Article

References (42)

1. Weel JF, van der Hulst RW, Gerrits Y, Roorda P, Feller M, Dankert J, et al. The interrelationship between cytotoxin-associated gene A, vacuolating cytotoxin, and Helicobacter pylori-related diseases. J Infect Dis 1996; 173:1171-1175.
2. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, Sibley RK. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325:1127-1131.
3. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Schistosomes, Liver Flukes and Helicobacter pylori. Vol 61. IARC monographs on the evaluation of carcinogenic risks to humans. Lyon: International Agency for Research on Cancer; 1994.
4. Tamer GS, Tengiz I, Ercan E, Duman C, Alioglu E, Turk UO. Helicobacter pylori seropositivity in patients with acute coronary syndromes. Dig Dis Sci 2009; 54:1253-1256.
5. Asma S, Boga C, Ozdogu H, Serin E. The association of pagophagia with Helicobacter pylori infection in patients with iron-deficiency anemia. Int J Hemato. 2009; 90:28-32.
6. Hernando-Harder AC, Booken N, Goerdt S, Singer MV, Harder H. Helicobacter pylori infection and dermatologic diseases. Eur J Dermatol 2009 [Epub ahead of print]
7. Sitas F, Forman D, Yarnell JW, Burr ML, Elwood PC, Pedley S, Marks KJ. Helicobacter pylori infection rates in relation to age and social class in a population of Welsh men. Gut 1991; 32:25-28.
8. Parsonnet J. The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9 (Suppl 2):45.
9. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection: the maastricht III consensus report. Gut 2007; 56:772-781.
10. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102:1808-1825.
11. Kearney DJ, Brousal A. Treatment of Helicobacter pylori infection in Clinical Practice in the United States. Dig Dis Sci 2000; 45:265-271.
12. Kadayifci A, Buyukhatipoglu H, Cemil Savas M, Simsek I. Eradication of Helicobacter pylori with triple therapy: an epidemiologic analysis of trends in Turkey over 10 years. Clin Ther 2006; 28:1960-1966.
13. Graham DY, Lew GM, Malaty HM, Evans DG, Evans DJ Jr, Klein PD, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102:493-496.
14. Mégraud F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53:1374-1384.
15. Glupczynski Y, Mégraud F, Lopez-Brea M, Andersen LP. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001; 20:820-823.
16. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing [Sixteenth informational supplement M100-S16].
17. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007; 26:343-357.
18. Mégraud F. Helicobacter pylori and macrolides. In: Schö nfeld W, Kirst HA, eds. Macrolide antibiotics. Berlin: Birkhä user Verlag; 2002. pp. 243-260.
19. De Francesco V, Margiotta M, Zullo A, Hassan C, Troiani L, Burattini O, et al. Clarithromycin-resistant genotypes and eradication of Helicobacter pylori. Ann Intern Med 2006; 144:94-100.
20. Marais A, Bilardi C, Cantet F, Mendz GL, Mégraud F. Characterization of the genes rdxA and frxA involved in metronidazole resistance in Helicobacter pylori. Res Microbiol 2003; 154:137-144.
21. Chisholm SA, Owen RJ. Mutations in Helicobacter pylori rdxA gene sequences may not contribute to metronidazole resistance. J Antimicrob Chemother 2003; 51:995-999.
22. Mendz GL, Mégraud F. Is the molecular basis of metronidazole resistance in microaerophilic organisms understood? Trends Microbiol 2002; 10:370.
23. Teare L, Peters T, Saverymuttu S, Owen R, Tiwari I. Antibiotic resistance in Helicobacter pylori. Lancet 1999; 353:242.
24. Osato MS, Reddy R, Reddy SG, Penland RL, Malaty HM, Graham DY. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med 2001; 161:1217-1220.
25. Torres J, Camorlinga-Ponce M, Perez-Perez G, Madrazo-De la Garza A, Dehesa M, Gonzalez-Valencia G, Munoz O. Increasing multidrug resistance in Helicobacter pylori strains isolated from children and adults in Mexico. J Clin Microbiol 2001; 39:2677-2680.
26. Perez Aldana L, Kato M, Nakagawa S, Kawarsaki M, Nagasako T, Mizushima T, et al. The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance. Helicobacter 2002; 7:306-309.
27. Kato M, Yamaoka Y, Kim JJ, Reddy R, Asaka M, Kashima K, et al. Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother 2000; 44:2214-2216.
28. McMahon BJ, Hennessy TW, Bensler JM, Bruden DL, Parkinson AJ, Morris JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003; 139:463-469.
29. Cabrita J, Oleastro M, Matos R, Manhente A, Cabral J, Barros R, et al. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chemother 2000; 46:1029-1031.
30. McGowan B, Bergin C, Bennett K, Barry M. Utilisation of antibiotic therapy in community practice. Ir Med J 2008; 101:273-276.
31. Hooton C, Dempsey C, Keohane J, O'Mahony S, Crosbie O, Lucey B. Helicobacter pylori: prevalence of antimicrobial resistance in clinical isolates. Br J Biomed Sci 2006; 63:113-116.
32. Ryan KA, van Doorn LJ, Moran AP, Glennon M, Smith T, Maher M. Evaluation of clarithromycin resistance and cagA and vacA genotyping of Helicobacter pylori strains from the west of Ireland using line probe assays. J Clin Microbiol 2001; 39:1978-1980.
33. Buckley MJ, Xia HX, Hyde DM, Keane CT, O'Morain CA. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. Dig Dis Sci 1997; 42:2111-2115.
34. European Study Group on Antibiotic Susceptibility of Helicobacter pylori. Results of a multicentre European Survey in 1991 of metronidazole resistance in Helicobacter pylori. Berlin/Heidelberg: Springer, European Journal of Clinical Microbiology and Infectious Diseases; 1992.
35. Williams D, O'Kelly P, Kelly A, Feely J. High failure rate of Helicobacter pylori regimens in general practise. Ir J Med Sci 2000; 169 (Suppl 2):87.
36. O'Connor JPA, Taneike I, O'Morá; in CA. Compliance with Helicobacter pylori eradication treatment: when and how? Ther Adv Gastroenterol 2009; 2:273-279.
37. Chisholm SA, Teare EL, Davies K, Owen RJ. Surveillance of primary antibiotic resistance of Helicobacter pylori at centres in England and Wales over a six-year period (2000-2005). Euro Surveill 2007; 12:pii= 721.
38. Keegan H, Ryan F, Malkin A, Griffin M, Lambkin H. Chlamydia trachomatis detection in cervical PreservCyt specimens from an Irish urban female population. Cytopathology 2009; 20:111-116.
39. Lui SY, Yeoh KG, Ho B. Metronidazole-resistant Helicobacter pylori is more prevalent in patients with nonulcer dyspepsia than in peptic ulcer patients in a multiethnic Asian population. J Clin Microbiol 2003; 41:5011-5014.
40. Seppä lä K, Kosunen TU, Veijola L, Sipponen P, Arkkila PE, Rautelin H, Tilvis R. Cure of Helicobacter pylori infection in all compliant patients: report on 644 subjects. Scand J Gastroenterol 2008; 43:1149-1150.
41. Rokkas T, Sechopoulos P, Robotis I, Margantis G, Pistiolas D. Cumulative H. pylori eradication rates in clinical practice by adopting first and second line regimens proposed by the Maastricht III consensus and a third line empirical regimen. Am J Gastroenterol 2009; 104:21-25.
42. Graham DY, Shiotani A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat Clin Pract Gastroenterol Hepatol 2008; 5:321-331.